Eli Lilly Keeps Obesity Pipeline Fresh with $1.3B Superluminal Partnership
The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new small molecule obesity medications for Lilly.Read more:
biospace.comBiotechnology